Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus
COVID-19 infected individuals with type 2 diabetes mellitus are at higher risk of COVID-19 related complications. Previous studies have yielded varying results regarding the effect of metformin, an antidiabetic drug, on the clinical outcomes of COVID-19 patients. In this retrospective observational...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIMS Press
2023-12-01
|
| Series: | AIMS Molecular Science |
| Subjects: | |
| Online Access: | https://www.aimspress.com/article/doi/10.3934/molsci.2023018?viewType=HTML |
| _version_ | 1797366753862352896 |
|---|---|
| author | Archana M Navale Vanila Devangan Arpit Goswami Vikas Sahu Lavanya S Devanshu Patel |
| author_facet | Archana M Navale Vanila Devangan Arpit Goswami Vikas Sahu Lavanya S Devanshu Patel |
| author_sort | Archana M Navale |
| collection | DOAJ |
| description | COVID-19 infected individuals with type 2 diabetes mellitus are at higher risk of COVID-19 related complications. Previous studies have yielded varying results regarding the effect of metformin, an antidiabetic drug, on the clinical outcomes of COVID-19 patients. In this retrospective observational study, we aim to assess the impact of pre-existing oral antidiabetic treatment on the clinical outcomes of COVID-19.
We analyzed in-patient data from hospital records, enrolling 150 COVID-19 patients with pre-existing diabetes mellitus. Among them, 75 were treated with metformin, while the remaining 75 were not. Exclusion criteria included patients with type I diabetes mellitus and those above 85 years of age. Fisher's exact test, Chi square test and unpaired t-test were used to analyze the data. There were no significant differences between the two groups in terms of age, gender, or drugs prescribed, aside from metformin. However, the metformin-treated group exhibited a significantly higher proportion of moderately ill patients compared to the non-metformin-treated group (P = 0.0011). Nonetheless, no statistically significant differences were observed between the groups regarding oxygen support requirement or duration of hospital stay. Notably, the metformin group showed distinct variations in haematological parameters, including lower serum creatinine levels (P = 0.0049), platelet count (P = 0.02) and HbA1c levels (P = 0.01). In conclusion, pre-existing metformin treatment did not impact the duration of hospital stay or the need for oxygen support in COVID-19 patients. However, the treatment did exert influence on other essential parameters. |
| first_indexed | 2024-03-08T17:09:11Z |
| format | Article |
| id | doaj.art-c9db43e4eaf74acbbf6a1fd35c4c7c61 |
| institution | Directory Open Access Journal |
| issn | 2372-0301 |
| language | English |
| last_indexed | 2024-03-08T17:09:11Z |
| publishDate | 2023-12-01 |
| publisher | AIMS Press |
| record_format | Article |
| series | AIMS Molecular Science |
| spelling | doaj.art-c9db43e4eaf74acbbf6a1fd35c4c7c612024-01-04T03:15:45ZengAIMS PressAIMS Molecular Science2372-03012023-12-0110431132110.3934/molsci.2023018Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitusArchana M Navale0Vanila Devangan1Arpit Goswami 2Vikas Sahu3Lavanya S 4Devanshu Patel51. Department of Pharmacology, Parul Institute of Pharmacy, Parul University, Limda, Gujarat, India2. Department of Pharmacy Practice, Parul Institute of Pharmacy, Parul University, Limda, Gujarat, India2. Department of Pharmacy Practice, Parul Institute of Pharmacy, Parul University, Limda, Gujarat, India2. Department of Pharmacy Practice, Parul Institute of Pharmacy, Parul University, Limda, Gujarat, India3. Department of Pharmacy Practice, PSG College of Pharmacy Practice, Peelamedu, Coimbatore, TN 641 004, India4. Department of Pharmacology, Parul Institute of Medical Science and Research, Gujarat, Parul University, Limda, Vadodara, IndiaCOVID-19 infected individuals with type 2 diabetes mellitus are at higher risk of COVID-19 related complications. Previous studies have yielded varying results regarding the effect of metformin, an antidiabetic drug, on the clinical outcomes of COVID-19 patients. In this retrospective observational study, we aim to assess the impact of pre-existing oral antidiabetic treatment on the clinical outcomes of COVID-19. We analyzed in-patient data from hospital records, enrolling 150 COVID-19 patients with pre-existing diabetes mellitus. Among them, 75 were treated with metformin, while the remaining 75 were not. Exclusion criteria included patients with type I diabetes mellitus and those above 85 years of age. Fisher's exact test, Chi square test and unpaired t-test were used to analyze the data. There were no significant differences between the two groups in terms of age, gender, or drugs prescribed, aside from metformin. However, the metformin-treated group exhibited a significantly higher proportion of moderately ill patients compared to the non-metformin-treated group (P = 0.0011). Nonetheless, no statistically significant differences were observed between the groups regarding oxygen support requirement or duration of hospital stay. Notably, the metformin group showed distinct variations in haematological parameters, including lower serum creatinine levels (P = 0.0049), platelet count (P = 0.02) and HbA1c levels (P = 0.01). In conclusion, pre-existing metformin treatment did not impact the duration of hospital stay or the need for oxygen support in COVID-19 patients. However, the treatment did exert influence on other essential parameters.https://www.aimspress.com/article/doi/10.3934/molsci.2023018?viewType=HTMLcovid-19metforminoral antidiabetic treatmentdiabetes mellitustherapeutic outcomehba1c |
| spellingShingle | Archana M Navale Vanila Devangan Arpit Goswami Vikas Sahu Lavanya S Devanshu Patel Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus AIMS Molecular Science covid-19 metformin oral antidiabetic treatment diabetes mellitus therapeutic outcome hba1c |
| title | Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus |
| title_full | Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus |
| title_fullStr | Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus |
| title_full_unstemmed | Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus |
| title_short | Effects of pre-existing metformin therapy on platelet count, serum creatinine, and hospitalization in COVID-19 patients with diabetes mellitus |
| title_sort | effects of pre existing metformin therapy on platelet count serum creatinine and hospitalization in covid 19 patients with diabetes mellitus |
| topic | covid-19 metformin oral antidiabetic treatment diabetes mellitus therapeutic outcome hba1c |
| url | https://www.aimspress.com/article/doi/10.3934/molsci.2023018?viewType=HTML |
| work_keys_str_mv | AT archanamnavale effectsofpreexistingmetformintherapyonplateletcountserumcreatinineandhospitalizationincovid19patientswithdiabetesmellitus AT vaniladevangan effectsofpreexistingmetformintherapyonplateletcountserumcreatinineandhospitalizationincovid19patientswithdiabetesmellitus AT arpitgoswami effectsofpreexistingmetformintherapyonplateletcountserumcreatinineandhospitalizationincovid19patientswithdiabetesmellitus AT vikassahu effectsofpreexistingmetformintherapyonplateletcountserumcreatinineandhospitalizationincovid19patientswithdiabetesmellitus AT lavanyas effectsofpreexistingmetformintherapyonplateletcountserumcreatinineandhospitalizationincovid19patientswithdiabetesmellitus AT devanshupatel effectsofpreexistingmetformintherapyonplateletcountserumcreatinineandhospitalizationincovid19patientswithdiabetesmellitus |